STERIS to Acquire Xodus Medical, Expanding Surgical Safety Portfolio
STE is trading near its 52-week low of $195.14 (9.9% above the low).
Summary
STERIS has signed a definitive agreement to acquire Xodus Medical and certain related affiliates for $2.1 billion at closing. Xodus Medical is a specialty surgical products company focused on patient and OR staff safety. The deal expands STERIS's healthcare consumables offering, aligning with its core infection prevention and procedural safety business. The acquisition is expected to be accretive to top-line growth, margins and adjusted earnings. This follows STERIS's recent $600M manufacturing investment and restructuring plan, signaling continued strategic expansion. The acquisition is expected to strengthen STERIS's position in the surgical safety market.
Updates
· SEC 8-K — STERIS Corporation agreed on October 11, 2026 to acquire Xodus Medical for $2.1 billion in cash, with up to $150 million in potential earnout consideration based on 2028 performance targets.
- Purchaser is STERIS Corporation, a wholly owned subsidiary of STERIS plc.
- Agreement is a Purchase and Sale Agreement.
- Sellers are Craig E. Kaforey, individually and as trustee of the Craig E. Kaforey Legacy Trust, and Mark A. Kaforey, individually and as trustee of the Mark A. Kaforey Legacy Trust.
- Acquisition is for all equity interests of Xodus Medical, Inc. and certain related affiliates.
- Purchase Agreement imposes customary confidentiality, non-solicitation and non-compete obligations on Sellers.
- Either Purchaser or Sellers may terminate Purchase Agreement if Acquisition has not occurred on or prior to July 12, 2027.
- Termination date may be extended under certain circumstances to January 11, 2028.
- Completion of Acquisition is subject to receipt of requisite regulatory approvals.
- Bridge facility commitment amounts may be reduced on a dollar-for-dollar basis based on net proceeds from permanent financing or asset sales.
- The Purchase and Sale Agreement was entered into on October 11, 2026.
- The $2.1 billion at closing is in cash, subject to customary adjustments.
- The Acquisition is expected to be financed primarily with debt.
- The bridge financing commitment was dated October 11, 2026.
- Craig E. Kaforey is a party to the Purchase Agreement individually, as trustee of the Craig E. Kaforey Legacy Trust, and as seller's representative.
- Acquisition is anticipated to close by December 31, 2026, subject to customary closing conditions and regulatory approvals.
- Bridge financing commitment parties are JPMorgan Chase Bank, N.A. and Goldman Sachs Bank USA.
- Bridge facility is for up to $2.0 billion in the aggregate.
- Bridge facility is a senior unsecured bridge facility.
At the time of this announcement, STE was trading at $214.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $20.9B. The 52-week trading range was $195.14 to $269.44. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.